Evonile Pharma, formerly Novartis India, has received board approval to raise up to ₹900 crore through a rights issue of partly paid-up equity shares. The company has formed a dedicated committee to finalize the issue price, entitlement ratio, and record date. Shareholders will now vote on the proposal via a postal ballot. This capital injection marks a significant shift as the firm transitions under its new corporate identity.
Evonile Pharma Announces ₹900 Crore Rights Issue
The Board of Directors has approved a fundraising plan of up to ₹900 crore through a rights issue. The issuance will consist of partly paid-up equity shares with a face value of ₹5 each.
Reader Takeaway: The rights issue aims to bolster capital; investors must monitor the forthcoming record date and pricing terms.
What just happened
Evonile Pharma Limited, formerly known as Novartis India Limited, has received board clearance for a major capital raise. The board has also initiated the process for shareholder approval through a postal ballot. To oversee the execution of this rights issue, the company has established a 'Rights Issue Committee' headed by Managing Director Vikas Gupta, alongside Dr. Jagriti Gupta and Shashank Sinha. This committee holds the mandate to finalize the issue price, rights entitlement ratio, and the record date.
Why this matters
A rights issue allows existing shareholders to purchase additional shares at a predetermined price. For investors, this provides an opportunity to increase their stake or potentially mitigate dilution, depending on the final terms of the offer. The formalization of this plan signifies the company's intent to strengthen its balance sheet following its recent rebranding. The company has also officially launched its new website, evonilepharma.com, to reflect its updated corporate identity.
What changes now
The proposal is currently in the preliminary stage. The company has yet to announce the specific record date—the cutoff date for shareholders to be eligible for the rights—and the exact price at which the shares will be offered. These details will be communicated in subsequent filings once the committee concludes its review and regulatory formalities are satisfied.
Risks to watch
Investors should note that the success of the capital raise is contingent upon both shareholder approval via the upcoming postal ballot and final sign-offs from regulatory bodies. Because commercial terms like the subscription price and entitlement ratio remain pending, the final impact on current share value is not yet fully quantifiable. Shareholders should wait for the official notification of the record date to make informed investment decisions.